Kornitzer Capital Management Inc. KS bought a new stake in Catalent Inc (NASDAQ:CTLT) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 199,310 shares of the company’s stock, valued at approximately $4,582,000.
Several other institutional investors have also recently bought and sold shares of the company. LS Investment Advisors LLC boosted its position in Catalent by 85.2% in the second quarter. LS Investment Advisors LLC now owns 7,131 shares of the company’s stock valued at $164,000 after buying an additional 3,280 shares in the last quarter. Strs Ohio boosted its position in Catalent by 17.7% in the second quarter. Strs Ohio now owns 9,300 shares of the company’s stock valued at $213,000 after buying an additional 1,400 shares in the last quarter. Louisiana State Employees Retirement System boosted its position in Catalent by 4.4% in the second quarter. Louisiana State Employees Retirement System now owns 28,500 shares of the company’s stock valued at $655,000 after buying an additional 1,200 shares in the last quarter. ING Groep NV purchased a new position in Catalent during the second quarter valued at approximately $690,000. Finally, Eagle Asset Management Inc. boosted its position in Catalent by 21.1% in the second quarter. Eagle Asset Management Inc. now owns 112,315 shares of the company’s stock valued at $2,582,000 after buying an additional 19,579 shares in the last quarter.
Catalent Inc (NASDAQ:CTLT) traded up 2.95% during mid-day trading on Tuesday, hitting $24.09. 529,779 shares of the stock were exchanged. The company has a 50-day moving average of $25.23 and a 200-day moving average of $25.57. The stock has a market capitalization of $3.01 billion and a PE ratio of 27.07. Catalent Inc has a 52 week low of $18.92 and a 52 week high of $32.24.
Catalent (NASDAQ:CTLT) last released its quarterly earnings results on Monday, August 29th. The company reported $0.52 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.53 by $0.01. The business had revenue of $532.20 million for the quarter. During the same period in the prior year, the firm earned $0.61 EPS. The firm’s revenue was up 4.3% compared to the same quarter last year. On average, equities analysts predict that Catalent Inc will post $1.40 EPS for the current fiscal year.
A number of research firms recently commented on CTLT. Stephens began coverage on shares of Catalent in a report on Tuesday. They issued an “overweight” rating on the stock. Zacks Investment Research cut shares of Catalent from a “hold” rating to a “strong sell” rating in a report on Monday, August 15th. Jefferies Group reaffirmed a “hold” rating on shares of Catalent in a report on Thursday, August 4th. Wells Fargo & Co. raised shares of Catalent from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 21st. Finally, Bank of America Corp. raised shares of Catalent from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a report on Monday, June 20th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. Catalent has an average rating of “Hold” and a consensus price target of $28.67.
In other Catalent news, major shareholder Blackstone Management Associat sold 17,100,705 shares of the stock in a transaction that occurred on Friday, September 9th. The shares were sold at an average price of $23.58, for a total value of $403,234,623.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent Inc (NASDAQ:CTLT).
Receive News & Ratings for Catalent Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc and related companies with MarketBeat.com's FREE daily email newsletter.